52-week Open Label Safety-Tolerability Study
← catalyst calendarNCT07369154 · readout ≤ 865 d
Sponsored by LB Pharmaceuticals Inc. (industry) · LBRX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
900estimated
Sites
23
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-23 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Intervention
- Drug: LB-102
Primary outcome
what the primary-completion date above is the date OFEvaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events.
measured 52 weeks
Permalink · LBRX's whole pipeline · Catalyst calendar · Every registered study · What changed